5.34
-6.29%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Trinity Biotech
Its shares trade under the ticker TRIB. It has been listed since 21 October 1992. In the fiscal year to 31 December 2025, it reported revenue of $43.8m and a net loss of $37.4m. At that date it held total assets of $105.2m and shareholders' equity of −$72.0m.
Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. The company is headquartered in Bray, Wicklow. The firm's products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company operates through two segments: the Americas and Rest of World. Its products are classified as POC, emergency medicine, clinical laboratory and blood bank screening. Its POC brands include Uni-Gold and Recombigen. Emergency medicine diagnostics refer to its acute care testing, STAT labs, pre/post-operative units, physician office labs and the central laboratory. Trinity Biotech supplies clinical laboratory market with reagent products and other products through its clinical chemistry business. Trinity Biotech's blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 21 Oct 1992
- Employees
- 579
- Website
- trinitybiotech.com ↗
- Head office
- IDA BUSINESS PARK, WICKLOW
- Incorporated in
- L2
- Classification
- In Vitro & In Vivo Diagnostic Substances
- Filer status
- Non-accelerated filer
Leadership
Pay as last reported
- Mr. John GillardPresident, Chief Executive Officer, Executive Director, since 2020$975,000
- Mr. Ronan O'caoimhFounder, Executive Director, since 1992$84,000
- Ms. Susan O'ConnorInterim Chief Financial Officer
- Dr. Gary KeatingChief Technology Officer
- Ms. Eibhlin KellyChief Information Officer
- Dr. Matthew WictomeVice President - Quality and Regulatory Affairs
- Dr. James WalshExecutive Director - Business Development, since 2005$83,000
- Mr. Colm MolloyGroup Director of Human Resources and Culture
- Mr. Tom LindsayNon-Executive Independent Director$57,000
- Mr. Andrew OmidvarNon-Executive Independent Director$57,000
- Mr. Eric RibnerInvestors Relations, since 2023
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 17
- Environment
- 17
- Social
- 32
- Governance
- 1
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Trinity Biotech's POC brands Uni-Gold and Recombigen lead in autoimmune disease detection.
- The company's clinical chemistry business supplies reagents for the clinical laboratory market.
- Trinity Biotech's blood bank screening unit ensures safe blood transfusions globally.
Weaknesses
- The Americas segment represents a significant portion of revenue but faces market saturation.
- Rest of World segment growth is limited by regulatory hurdles in emerging markets.
- The company's reliance on clinical laboratory products may hinder innovation in new areas.
Opportunities
- Expanding POC diagnostics in the Americas segment for infectious disease testing.
- Growing demand for blood bank screening in Rest of World due to increased transfusions.
- Increasing diabetes diagnostics in the clinical laboratory market segment.
Threats
- Regulatory changes in the Health Care sector could impact product approvals.
- Competition from established players in the clinical laboratory market.
- Economic downturns may reduce healthcare spending in the Rest of World segment.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.